Substituted Pyridoisoquinolines for Sustained VMAT2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing VMAT2 inhibitors like (±)-tetrabenazine have a narrow therapeutic window, extensive first-pass metabolism, and require frequent dosing due to short half-life, leading to significant side effects and compliance issues, necessitating improved compounds with longer half-life and lower clearance for chronic administration.
Innovation Solution
Development of substituted pyrido[2,1-a]isoquinoline compounds and their pharmaceutically acceptable salts, which act as potent VMAT2 inhibitors with improved pharmacokinetics, offering reduced dosing frequency and enhanced patient compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If (±)-tetrabenazine is used as a VMAT2 inhibitor, then potent inhibition of catecholamine uptake by VMAT2 is achieved, but extensive first pass metabolism occurs resulting in little or no drug observed in systemic circulation
Solution Approach 1:
The patent modifies the chemical structure of tetrabenazine by substituting the isobutyl group with various alkyl, cycloalkyl, aryl, and heteroaryl groups. These structural parameter changes alter the drug's metabolic stability and pharmacokinetic properties, reducing first-pass metabolism while maintaining VMAT2 inhibition potency.
Solution Approach 2:
The patent creates a series of hybrid compounds combining the core pyridoisoquinoline structure with diverse substituent groups (alkyl, cycloalkyl, aryl, heteroaryl). These composite molecular structures achieve optimal balance between metabolic stability and pharmacological activity.
2Reliability
If (±)-tetrabenazine is administered, then VMAT2 inhibition is achieved, but the short half-life requires frequent dosing (TID regimen)
Solution Approach 1:
The patent modifies molecular parameters including lipophilicity, molecular weight, and structural rigidity through various substitutions. These changes increase plasma protein binding and reduce clearance, thereby extending the drug half-life from approximately 5 hours to longer durations that support once-daily dosing.
3Reliability
If (±)-tetrabenazine is used to treat hyperkinetic disorders, then pharmacological activity is achieved, but the narrow therapeutic window requires careful dose titration and leads to side effects
Solution Approach 1:
The patent optimizes the therapeutic index by modifying molecular parameters to achieve slower, more sustained drug release and more stable plasma concentrations. This reduces peak-to-trough fluctuations and maintains drug levels within the therapeutic window, minimizing side effects while preserving efficacy.
4Ease of operation
If (±)-tetrabenazine is administered orally, then drug delivery is achieved, but rapid and extensive metabolism in vivo occurs
Solution Approach 1:
The patent introduces metabolic stability parameters into the molecular design by selecting substituent groups that are resistant to hepatic metabolism. The chosen substituents (cycloalkyl, aryl, heteroaryl groups) provide enhanced metabolic stability while maintaining oral bioavailability.
Data Source
AI summary
This disclosure relates generally to VMAT2 inhibitor compounds of Formula (Ia):and pharmaceutically acceptable salts thereof, as well as compositions and methods related thereto.